Sunshine Biopharma (SBFM) EBT (2011 - 2026)

Sunshine Biopharma has reported EBT for 15 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 1.96% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$6.0 million (down 613.89% YoY), and the FY2025 full-year result was -$6.0 million, down 630.77% from the prior year.
• EBT for Q1 2026 stood at -$1.2 million, up from -$1.7 million in the prior quarter.
• The five-year high for EBT was $4.2 million in Q4 2024, with the low at -$23.3 million in Q4 2022.
• Historically, EBT has averaged -$2.2 million across 5 years, with a median of -$1.2 million in 2025.
• Annual changes were most pronounced in 2022 — EBT plunged 3589.5% — and 2024, when it surged 508.23%.
• Sunshine Biopharma's EBT stood at -$23.3 million in 2022, then surged by 95.58% to -$1.0 million in 2023, then surged by 508.23% to $4.2 million in 2024, then sank by 141.21% to -$1.7 million in 2025, then grew by 28.21% to -$1.2 million in 2026.
• The last three EBT figures came in at -$1.2 million (Q1 2026), -$1.7 million (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.